| Positive Rankings |
Estimated Revenue Growth
Syndax Pharmaceuticals rank is 20 |
Low vPut/Call
Syndax Pharmaceuticals has a low Put/Call ratio of 0.06 on active options expiring within the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Syndax Pharmaceuticals is ranked 83. |
90 Day Gain
Syndax Pharmaceuticals rank is 190 |
Low Put/Call
Syndax Pharmaceuticals has a low Put/Call ratio of 0.07 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Syndax Pharmaceuticals is ranked 200. |
Target Prices
The average analysts' target price is $16.00 for Syndax Pharmaceuticals using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Syndax Pharmaceuticals is ranked 859. |
10 Day Gain
Syndax Pharmaceuticals rank is 1228 |
Debt-to-Equity
Syndax Pharmaceuticals rank is 1733 |
Up EPS Surprise
Syndax Pharmaceuticals beat the consensus earnings estimate when it last reported quarterly earnings. |
| Negative Rankings |
Price-to-Sales
Syndax Pharmaceuticals rank is 52 |
Negative Net Margin
Syndax Pharmaceuticals rank is 75 |
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Syndax Pharmaceuticals is ranked 124. |
Negative ROE
Syndax Pharmaceuticals rank is 150 |
Negative ROA
Syndax Pharmaceuticals rank is 189 |
Price-to-Book
Syndax Pharmaceuticals rank is 328 |
